insights_auto
Per què A1LN34 ha baixat 2,52%?
Aprofundeix méschevron_right
A1LN34:BVMF
Alnylam Pharmaceuticals Inc Bdr
55,80Â BRL
arrow_downward
-2,52%(-1,44) 1d
13 d’oct., 13:06:17 GMT-3 · BRL
search
Tots els sĂmbols
| SĂmbol | Preu | Canvi | Percentatge de canvi |
|---|
insights_autoS'estan generant les estadĂstiques principals per a A1LN34...
Obre
55,80Â BRL
Alt
55,80Â BRL
Baix
55,80Â BRL
CapitalitzaciĂł borsĂ ria
29,89Â kM
Volum mitjĂ
840,00
Volum
21,00
Alt 52 setmanes
132,40Â BRL
Baix 52 setmanes
50,25Â BRL
Accions en circulaciĂł
133,81Â M
Nombre d'empleats
2Â k
Obre
55,80Â BRL
Alt
55,80Â BRL
Baix
55,80Â BRL
CapitalitzaciĂł borsĂ ria
29,89Â kM
Volum mitjĂ
840,00
Volum
21,00
Alt 52 setmanes
132,40Â BRL
Baix 52 setmanes
50,25Â BRL
Accions en circulaciĂł
133,81Â M
Nombre d'empleats
2Â k
NotĂcies
De fonts web i partners de notĂcies
Investing.com Canada
·
fa 10 hores
Form 4 Alnylam Pharmaceuticals Inc For: 13 October By Investing.com
Investing.com
·
fa 2 dies
Alnylam EVP Bryan Supran sells $398,855 in shares
Simply Wall Street
·
fa 2 dies
How Securities Fraud Scrutiny Will Impact Alnylam Stock Investors
Yahoo Finance
·
fa 3 dies
Alnylam vs. Ionis: Here's the Better Bad-News Buy
Perfil
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Sobre Alnylam Pharmaceuticals Inc Bdr